Effects of recombinant human canstatin protein in the treatment of pancreatic cancer

Figure 5 In vivo antitumor effects in a xenograft model. The in vivo antitumor effect of the canstatin was analyzed in a SW1990 human pancreatic cancer cell orthotopic xenograft model. A: Tumor volumes in different groups: Canstatin 5 mg/kg or 10 mg/kg treatment showed a significantly stronger anti-tumor effect, compared with the PBS treated group (^bP < 0.01); B: MVD in xenograft models: significant inhibition of angiogenesis was observed in groups treated with canstatin 5 mg/kg or 10 mg/kg compared with that in the control group (^aP < 0.05, ^bP < 0.01, respectively); C: CD34 immunohistochemistry in group treated with PBS (× 200): tumor sections showed extensive angiogenesis; D: CD34 immunohistochemistry in group treated with canstatin (× 200): tumor sections showed obviously decreased new vessels with a small focus of necrosis.